Arcus Biosciences Inc
NYSE:RCUS

  • LAST PRICE
    17.4700
  • TODAY'S CHANGE (%)
    0.1800 (1.0411%)
  • Bid / Lots
    16.7000/ 10
  • Ask / Lots
    18.2000/ 1
  • Open / Previous Close
    17.6400 / 17.2900
  • Day Range
    17.2531
    17.9600
  • 52 Week Range
    13.5200
    20.3100
  • Volume
    501,207

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Dec 3, 2024

      Show headlines and story abstract

    • 4:35PM ET on Tuesday Dec 03, 2024 by Dow Jones
      Companies Mentioned: RCUS

      Arcus Biosciences Announces New Employment Inducement Grants
      HAYWARD, Calif.--(BUSINESS WIRE)--December 03, 2024--
      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 10,000 shares of the Company's common stock at an exercise price per share of $14.56, which was the closing price on November 25, 2024, and restricted stock units to acquire a total of 5,000 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

  • Nov 19, 2024

  • Nov 12, 2024

      Show headlines and story abstract

    • 4:35PM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: RCUS

      Arcus Biosciences Announces New Employment Inducement Grants
      HAYWARD, Calif.--(BUSINESS WIRE)--November 12, 2024--
      Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 14,100 shares of the Company's common stock at an exercise price per share of $17.85, which was the closing price on November 8, 2024, and restricted stock units to acquire a total of 7,050 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

Peers Headlines